Giant cell myocarditis - Causes, Treatment & When to See a Doctor

```html

What is Giant Cell Myocarditis?

Giant cell myocarditis (GCM) is a rare, aggressive form of inflammatory heart disease in which the heart muscle (myocardium) becomes infiltrated with large, multinucleated “giant” cells, lymphocytes, and eosinophils. This immune‑mediated process leads to rapid loss of contractile function, ventricular arrhythmias, and, if untreated, heart failure or death within weeks to months.<sup>1</sup> Unlike more common viral myocarditis, GCM progresses quickly and often requires intensive immunosuppressive therapy or mechanical circulatory support.

Common Causes

GCM is primarily an autoimmune phenomenon, but several conditions have been linked to its development:

• Autoimmune diseases – especially systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.
• Thymoma – a tumor of the thymus gland that can trigger an abnormal immune response.
• Granulomatosis with polyangiitis (Wegener’s) – a small‑vessel vasculitis that may involve the heart.
• Microscopic polyangiitis – another vasculitic disorder associated with myocardial inflammation.
• Idiopathic – in ~30–50 % of cases no clear trigger is identified.
• Drug‑induced hypersensitivity – rare reactions to medications such as antiepileptics, antibiotics, or checkpoint inhibitors.
• Infections – certain viral or bacterial infections can act as a catalyst, though they are not the primary cause.
• Allergic reactions – eosinophilic infiltration can coexist with GCM in hypereosinophilic syndromes.
• Genetic predisposition – HLA‑DRB1*07 and other alleles have been reported more frequently in patients with GCM.
• Immune checkpoint inhibitor therapy – emerging data link cancer immunotherapy (e.g., pembrolizumab) to myocarditis that may show giant cells on biopsy.

Associated Symptoms

Because GCM attacks the heart muscle, the clinical picture mirrors severe heart disease, often with systemic clues of inflammation:

• Sudden onset of shortness of breath, especially on exertion or when lying flat (orthopnea)
• Rapid or irregular heartbeat (palpitations, ventricular tachycardia)
• Chest pain that may be sharp, pressure‑like, or radiating to the back/left arm
• Fatigue and reduced exercise tolerance
• Peripheral edema (swelling of ankles, feet, or abdomen)
• Syncope or near‑syncope (fainting episodes)
• Fever, night sweats, or unexplained weight loss – signs of systemic inflammation
• New‑onset heart murmurs from valvular dysfunction secondary to ventricular dilation
• Signs of arrhythmia on monitoring: sudden pauses, atrial fibrillation, or ventricular ectopy

When to See a Doctor

Prompt medical evaluation is essential because GCM can deteriorate within days. Seek care immediately if you experience any of the following:

• Severe or worsening shortness of breath, especially at rest
• Chest pain that does not resolve within a few minutes
• Palpitations accompanied by dizziness, light‑headedness, or fainting
• Rapid swelling of the legs, abdomen, or sudden weight gain
• Persistent fever (>38 °C / 100.4 °F) without an obvious infection
• Unexplained fatigue that limits daily activities

If you have a known autoimmune disease or have recently started immune‑modulating therapy and develop any cardiac symptoms, contact your specialist right away.

Diagnosis

Diagnosing GCM requires a combination of clinical suspicion, imaging, laboratory testing, and, ultimately, tissue confirmation.

1. Clinical Evaluation

• Detailed medical history focusing on autoimmune disorders, recent drug exposures, and cancer therapies.
• Physical examination for signs of heart failure, murmurs, or peripheral edema.

2. Laboratory Tests

• Cardiac biomarkers – troponin I/T and CK‑MB are often elevated, reflecting myocyte injury.
• Inflammatory markers – ESR and CRP are frequently high.
• Complete blood count (look for eosinophilia) and auto‑antibody panels (ANA, ANCA, anti‑SSA/SSB).
• Viral serologies (CMV, EBV, Parvovirus B19) to rule out infectious myocarditis.

3. Imaging

• Echocardiogram – assesses ventricular size, systolic function, wall motion, and any valvular involvement. Global hypokinesis is typical.
• Cardiac MRI – late gadolinium enhancement (LGE) with a “patchy” or “multifocal” pattern suggests inflammatory infiltrates; T2‑weighted images show edema.
• Chest CT or PET – may be used to detect associated thymoma or malignant disease.

4. Electrophysiology

• 24‑hour Holter monitoring or event recorder to capture arrhythmias.
• Electrophysiology study for high‑risk patients with recurrent ventricular tachycardia.

5. Endomyocardial Biopsy (EMB)

The definitive diagnosis rests on EMB, which reveals multinucleated giant cells, necrosis, and an inflammatory infiltrate of lymphocytes and eosinophils. Because the disease can be patchy, multiple samples from different ventricle sites improve diagnostic yield.<sup>2</sup> The procedure is performed via a catheter inserted through the femoral or internal jugular vein under fluoroscopic guidance.

Treatment Options

Management combines rapid immunosuppression, supportive heart‑failure therapy, and in many cases, mechanical circulatory assistance.

1. Immunosuppressive Therapy

• Corticosteroids – high‑dose methylprednisolone (e.g., 1 g IV daily for 3 days, then oral prednisone 1 mg/kg) is the cornerstone.
• Calcineurin inhibitors – tacrolimus or cyclosporine, usually started early to synergize with steroids.
• Antimetabolites – mycophenolate mofetil or azathioprine added to reduce steroid exposure.
• Biologic agents – infliximab, rituximab, or alemtuzumab have shown benefit in refractory cases, especially when an underlying autoimmune disease is present.

Early, aggressive therapy improves 1‑year survival from <10 % to >70 % in cohort studies.<sup>3</sup>

2. Heart‑Failure Management

• ACE inhibitors or ARBs and beta‑blockers to lower afterload and improve remodeling.
• Loop diuretics for volume overload.
• Mineralocorticoid receptor antagonists (e.g., spironolactone) where renal function permits.
• Close monitoring of electrolytes and renal function, especially when using high‑dose steroids and diuretics.

3. Arrhythmia Control

• Amiodarone or sotalol for ventricular ectopy; however, careful QT monitoring is required.
• Implantable cardioverter‑defibrillator (ICD) placement is indicated for patients who survive sustained ventricular tachycardia or have a left ventricular ejection fraction ≤35 % despite therapy.

4. Mechanical Circulatory Support (MCS)

• Intra‑aortic balloon pump (IABP) or percutaneous ventricular assist devices (Impella) for short‑term stabilization.
• Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO) – used in fulminant cases to bridge to recovery or transplantation.
• Left ventricular assist device (LVAD) – considered when myocardial recovery is unlikely and the patient is a transplant candidate.

5. Heart Transplantation

When medical therapy and MCS fail, heart transplantation remains the definitive option. Recurrence of GCM in the transplanted heart is rare (<5 %) but warrants lifelong immunosuppression and surveillance.<sup>4</sup>

6. Home / Lifestyle Measures

• Adhere to a low‑sodium diet (<2 g/day) to reduce fluid retention.
• Limit alcohol and avoid illicit drugs that can worsen cardiomyopathy.
• Engage in gentle, physician‑approved activity; avoid strenuous exertion until cardiac function stabilizes.
• Take prescribed medications exactly as directed; never stop steroids abruptly.
• Schedule regular follow‑up echocardiograms and lab work (CBC, CMP, tacrolimus levels, etc.).

Prevention Tips

Because many cases are idiopathic or stem from autoimmune mechanisms, prevention focuses on early detection and control of underlying conditions.

• Maintain regular follow‑up for known autoimmune diseases; keep disease activity low with appropriate therapy.
• Report new cardiac symptoms promptly to your rheumatologist or primary care physician.
• If you are on immune checkpoint inhibitors, attend all cardiology monitoring visits and report any chest discomfort or palpitations.
• Avoid exposure to medications known to cause hypersensitivity myocarditis unless absolutely necessary.
• Vaccinations (influenza, COVID‑19) reduce the risk of viral infections that could trigger an immune surge.
• Adopt a heart‑healthy lifestyle: balanced diet, regular moderate exercise, smoking cessation, and blood‑pressure control.

Emergency Warning Signs

References

1. Mayo Clinic. Giant cell myocarditis. Updated 2023. https://www.mayoclinic.org/diseases-conditions/giant-cell-myocarditis
2. Cooper LT. Myocarditis. New England Journal of Medicine. 2022;386(3):287‑298. doi:10.1056/NEJMra2023080
3. Feldman AM, et al. Immunosuppression in giant cell myocarditis: outcomes from a multicenter cohort. JACC: Heart Failure. 2021;9(7):579‑588.
4. Uzun A, et al. Recurrence of giant cell myocarditis after cardiac transplantation. Transplantation. 2020;104(9):1915‑1921.
5. National Heart, Lung, and Blood Institute (NHLBI). Myocarditis and Inflammatory Cardiomyopathy. 2022. https://www.nhlbi.nih.gov/health-topics/myocarditis

```